Literature DB >> 10517878

Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines.

S H Garrett1, M A Sens, D Shukla, S Nestor, S Somji, J H Todd, D A Sens.   

Abstract

BACKGROUND: Expression of metallothionein isoform 3 (MT-3) was initially reported to be confined to neural tissues. However, it was recently demonstrated that MT-3 is expressed in epithelial cells of the human kidney. This motivated the current examination of the expression of MT-3 in the human prostate.
METHODS: Immunohistochemistry (IHC) was used to localize the expression of MT-3, RT-PCR to determine the expression of MT-3 mRNA, and Western blot analysis to determine the level of MT-3 protein.
RESULTS: Selected epithelial and stromal cells of the normal human prostate were shown to have low levels of MT-3 expression. MT-3 was increased in prostatic intraepithelial neoplasia (PIN) lesions and further increased in a highly variable fashion in prostatic adenocarcinoma. In some adenocarcinomas, MT-3 expression exceeded that of nerve. Three cell culture models of prostate cancer were also shown to variably express MT-3. Restriction enzyme analysis confirmed the expression of MT-3 in the cells and tissues.
CONCLUSIONS: MT-3 is expressed in the normal human prostate, and expression is enhanced and highly variable in PIN lesions and primary prostate cancer cells. The variable nature of MT-3 expression was also noted in commonly utilized prostate cancer cell lines. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517878     DOI: 10.1002/(sici)1097-0045(19991101)41:3<196::aid-pros7>3.0.co;2-u

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis.

Authors:  M A Sens; S Somji; S H Garrett; C L Beall; D A Sens
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Chemistry and biology of mammalian metallothioneins.

Authors:  Milan Vašák; Gabriele Meloni
Journal:  J Biol Inorg Chem       Date:  2011-06-07       Impact factor: 3.358

3.  Identification of mouse brain proteins associated with isoform 3 of metallothionein.

Authors:  David W Lahti; John D Hoekman; Abigail M Tokheim; Bruce L Martin; Ian M Armitage
Journal:  Protein Sci       Date:  2005-03-31       Impact factor: 6.725

4.  Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

Authors:  S L El Sharkawy; N F Abbas; M A Badawi; M A El Shaer
Journal:  J Clin Pathol       Date:  2006-03-30       Impact factor: 3.411

5.  Metallothioneins and brain injury: What transgenic mice tell us.

Authors:  Juan Hidalgo
Journal:  Environ Health Prev Med       Date:  2004-05       Impact factor: 3.674

Review 6.  Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.

Authors:  Sook-Jeong Lee; Jae-Young Koh
Journal:  Mol Brain       Date:  2010-10-26       Impact factor: 4.041

7.  Reaction of human metallothionein-3 with cisplatin and transplatin.

Authors:  Andrei V Karotki; Milan Vasák
Journal:  J Biol Inorg Chem       Date:  2009-06-18       Impact factor: 3.358

8.  Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells.

Authors:  Takashi Otsuka; Aki Hamada; Kazuhiro Iguchi; Shigeyuki Usui; Kazuyuki Hirano
Journal:  Biomed Rep       Date:  2013-05-17

9.  Role of metallothioneins in benign and malignant thyroid lesions.

Authors:  Bartosz Pula; Pawel Domoslawski; Marzena Podhorska-Okolow; Piotr Dziegiel
Journal:  Thyroid Res       Date:  2012-12-28

10.  Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas.

Authors:  Dunfa Peng; Tian-Ling Hu; Aixiang Jiang; Mary Kay Washington; Christopher A Moskaluk; Regine Schneider-Stock; Wael El-Rifai
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.